EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia

Colgate Active Salt redefines oral hygiene with a new and improved formula

Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus

Vivity reaches 1 million milestone

Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology

Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours

MTD acquires Ypsomed's pen needle and BGM businesses

This acquisition enables MTD to open new, strategic markets

Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024

Concept Medical receives USFDA approval for sirolimus drug-coated balloon

For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations

WuXi Biologics breaks ground on CRDMO Center in Singapore

The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network